Citadel Advisors’s Zosano Pharma Corporation ZSAN Stock Holding History

Citadel Advisors’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-814	Closed	-$6K	–	14886
2022 Q1	$6K	Buy	+814	New	+$8.96K	﹤0.01%	13422
2021 Q4	–	Sell	-4,176	Closed	-$105K	–	15364
2021 Q3	$105K	Buy	4,176 +3,028	+264%	+$78.5K	﹤0.01%	12820
2021 Q2	$38K	Sell	1,148 -3,444	-75%	-$111K	﹤0.01%	13435
2021 Q1	$199K	Buy	+4,592	New	+$192K	﹤0.01%	11713
2020 Q2	–	Sell	-1,322	Closed	-$26K	–	10772
2020 Q1	$26K	Buy	+1,322	New	+$44.3K	﹤0.01%	9238
2018 Q4	–	Sell	-378	Closed	-$54K	–	10019
2018 Q3	$54K	Buy	+378	New	+$55.4K	﹤0.01%	8791
2018 Q1	–	Sell	-97	Closed	-$35K	–	8988
2017 Q4	$35K	Buy	+97	New	+$48.7K	﹤0.01%	7734

Other funds holding ZSAN

CDIA

Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Citadel Advisors's ZSAN Position: Q2 2022 in Review

Citadel Advisors sold out of Zosano Pharma Corporation (ZSAN) in Q2 2022, closing a stake of 814 shares — an estimated $6K sold.

Citadel Advisors first reported a position in ZSAN in Q4 2017 and held it in 7 quarters. The position peaked at $199K in Q1 2021. 3 funds tracked by Wall St. Rank hold ZSAN as of Q2 2022.

Citadel Advisors reported no remaining Zosano Pharma Corporation position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 814 Zosano Pharma Corporation shares in Q2 2022, an estimated $6K.
Citadel Advisors first reported a position in Zosano Pharma Corporation in Q4 2017 and held it in 7 quarters.
Citadel Advisors's Zosano Pharma Corporation position peaked at $199K in Q1 2021.
3 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.